

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

IN RE: SUBPOENA NO. 25-1431-014

MISCELLANEOUS ACTION

No. 25-mc-0039-MAK

**MOTION FOR LEAVE TO FILE *AMICUS BRIEF* IN SUPPORT OF MOTION TO
LIMIT THE *SUBPOENA DUCES TECUM* ISSUED ON JUNE 12, 2025**

Proposed Amici Curiae Josh Shapiro in his official capacity as Governor of Pennsylvania, the Commonwealth of Massachusetts, and other states (together, “Amici”), respectfully move for leave to file an amicus brief in support of the Motion to Limit the *Subpoena Duces Tecum* Issued on June 12, 2025 filed by the Children’s Hospital of Philadelphia (CHOP) (ECF 1). The proposed amicus brief, which does not exceed 20 pages consistent with the limits set on memoranda by Section IV(C) of this Court’s Policies and Procedures, is attached as **Exhibit 1**.

District courts have “inherent authority” to grant the filing of amicus briefs. *Liberty Res., Inc. v. Philadelphia Hous. Auth.*, 395 F. Supp. 2d 206, 209 (E.D. Pa. 2005); *accord In re Nazi Era Cases Against German Defendants Litig.*, 153 F. App’x 819, 827 (3d Cir. 2005). Amicus briefs are “especially proper” when “an issue of general public interest is at stake” or where amicus briefs “will ensure a complete and plenary presentation of difficult issues.” *Liberty Res., Inc.*, 395 F. Supp. 2d at 209 (cleaned up).

Amici are sovereign states with an interest in the regulation of the practice of medicine within their own borders, including by licensing doctors and other medical professionals, implementing standards of care for a wide variety of medical procedures and treatments, and enforcing those standards and other related regulations. This includes the provision of medically

necessary gender-affirming care for youth under 19.

Amici support CHOP's motion to limit the subpoena served by the Department of Justice because it demands highly confidential patient information without justification; it threatens to interfere with the doctor-patient relationship; it seeks to intimidate medical providers from offering critical, medically necessary health care; and it rests on a flawed legal justification that would intrude on the States' authority to regulate the practice of medicine within their borders.

The proposed brief will assist the Court in its consideration of the pending motion because Amici can speak to the harm DOJ's improper investigations will inflict on them and their residents. Many Amici have sought to enjoin the unlawful and improper campaign by DOJ to intimidate providers of gender-affirming care to abandon their patients. *See Massachusetts v. Trump*, 25-cv-12162 (D. Mass.) (Aug. 1, 2025).

As explained in the proposed amicus brief, the position taken by DOJ in the related matter, DOJ Mem., *In Re: Administrative Subpoena No. 25-1431-014*, No. 25-54, ECF No. 16 (E.D.Pa.), further subjects Amici to harm by taking an expansive and harmful view of the Food Drug and Cosmetic Act (FDCA) that is contrary to settled law and could subject research and medical institutions in Amici States to significant liability. Amici, their medical institutions, and their transgender residents will all be harmed if DOJ is permitted to continue to harass and improperly investigate medical providers with the express intent of eliminating medically necessary gender-affirming care. Further, the expansive and unprecedented expansion in the theory of liability under the FDCA could subject research and medical institutions in Amici to considerable consequences.

Counsel for Amici have conferred with counsel of record for the parties in this case. Counsel for CHOP consent to Amici's motion for leave to file an amicus brief. Counsel for the

United States stated that they take no position on Amici's motion.

For these reasons, Amici respectfully request that the Court grant this motion and docket the attached amicus brief.

DATE: October 27, 2025

Respectfully submitted,

JENNIFER SELBER

General Counsel

MICHAEL J. FISCHER

Executive Deputy General Counsel

/s/ Aimee D. Thomson

AIMEE D. THOMSON

Deputy General Counsel

Governor's Office of General Counsel

30 N. 3rd St., Suite 200

Harrisburg, PA 17101

Tel.: (223) 234-4986

aimeethomson@pa.gov

Attorneys for Governor Josh Shapiro

CERTIFICATE OF SERVICE

I, Aimee D. Thomson, hereby certify that I have this day, October 27, 2025, served the foregoing document upon all parties of record by electronically filing to all ECF-registered parties.

/s/ Aimee D. Thomson
Aimee D. Thomson

EXHIBIT 1

IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA

IN RE: SUBPOENA NO. 25-1431-014

MISCELLANEOUS ACTION

No. 25-mc-0039-MAK

**BRIEF OF GOVERNOR JOSH SHAPIRO, MASSACHUSETTS, CALIFORNIA,
COLORADO, CONNECTICUT, DELAWARE, THE DISTRICT OF COLUMBIA,
ILLINOIS, MARYLAND, MINNESOTA, NEVADA, NEW JERSEY, NEW YORK,
OREGON, VERMONT, AND WASHINGTON AS *AMICI CURIAE* IN SUPPORT OF
MOTION TO LIMIT THE *SUBPOENA DUCES TECUM* ISSUED ON JUNE 12, 2025**

ANDREA JOY CAMPBELL
Attorney General of Massachusetts
ALLYSON SLATER
Director, Reproductive Justice Unit
ADAM M. CAMBIER
MORGAN CARMEN
JAK KUNDL
Assistant Attorneys General
One Ashburton Place
Boston, MA 02108
Tel.: (617) 727-2200
adam.cambier@mass.gov

*Attorneys for the Commonwealth of
Massachusetts*

October 27, 2025

JENNIFER SELBER
General Counsel
MICHAEL J. FISCHER
Executive Deputy General Counsel
AIMEE D. THOMSON
Deputy General Counsel
Governor's Office of General Counsel
30 N. 3rd St., Suite 200
Harrisburg, PA 17101
Tel.: (223) 234-4986
aimeethomson@pa.gov

Attorneys for Governor Josh Shapiro

TABLE OF CONTENTS

TABLE OF AUTHORITIES	iii
INTRODUCTION AND STATEMENT OF INTERESTS.....	1
ARGUMENT	3
I. If enforced, the subpoena would harm the inherent privacy rights of Amici’s residents.	3
II. If enforced, the subpoena would interfere with Amici’s authority to regulate the practice of medicine.	6
III. DOJ adopts an overly expansive—and unprecedented—interpretation of the FDCA.	10
A. Off-label use of approved drugs where medically appropriate is permissible under the FDCA.	11
B. DOJ wrongly sweeps off-label prescribing and dispensing into the FDCA’s prohibitions concerning distribution and promotion of unapproved drugs.	13
1. Purchasing, storing, and administering approved medications does not give rise to criminal liability under the FDCA.	13
2. Practitioners’ provision of information about off-label uses does not subject medical providers to liability for misbranding.....	15
C. DOJ’s expansive interpretation of the FDCA jeopardizes entire fields of medicine.....	17
CONCLUSION.....	20

TABLE OF AUTHORITIES

Cases

<i>Allegheny Reprod. Health Ctr. v. Pa. Dep’t of Hum. Servs.</i> , 309 A.3d 808 (Pa. 2024)	4, 5
<i>Ass’n of Am. Physicians & Surgeons v. U.S. Food & Drug Admin.</i> , 13 F.4th 531 (6th Cir. 2021).....	10, 20
<i>Barsky v. Bd. of Regents</i> , 347 U.S. 442 (1954).....	7
<i>Buckman Co. v. Plaintiffs’ Legal Comm.</i> , 531 U.S. 341 (2001).....	7, 10, 11
<i>Coleman v. W.C.A.B.</i> , 842 A.2d 349 (Pa. 2004).....	4
<i>Commonwealth v. Murray</i> , 223 A.2d 102 (Pa. 1966).....	3
<i>Commonwealth v. Shaw</i> , 770 A.2d 295 (Pa. 2001)	5
<i>Denoncourt v. State Ethics Commission</i> , 470 A.2d 945 (Pa. 1983)	4, 5
<i>Dent v. West Virginia</i> , 129 U.S. 114 (1889)	6
<i>Driscoll v. Corbett</i> , 69 A.3d 197 (Pa. 2013).....	4
<i>Gonzales v. Carhart</i> , 550 U.S. 124 (2007)	7
<i>Gonzales v. Oregon</i> , 546 U.S. 243 (2006).....	7
<i>Haddad v. Gopal</i> , 787 A.2d 975 (Pa. Super. 2001)	3
<i>Hillsborough Cnty., Fla. v. Automated Med. Lab’ys, Inc.</i> , 471 U.S. 707 (1985)	3, 7
<i>In re “B,”</i> 394 A.2d 419 (Pa. 1978)	6
<i>In re June 1979 Allegheny Cnty. Investigating Grand Jury</i> , 415 A.2d 73 (Pa. 1980)	5
<i>In re Schering Plough Corp. Intron/Temodar Consumer Class Action</i> , 678 F.3d 235 (3d Cir. 2012).....	12, 15
<i>In re Zofran (Ondansetron) Prods. Liab. Litig.</i> , 541 F. Supp. 3d 164 (D. Mass. 2021)	12
<i>John M. v. Paula T.</i> , 571 A.2d 1380 (Pa. 1990)	5
<i>League of Women Voters v. Commonwealth</i> , 178 A.3d 737 (Pa. 2018).....	4
<i>Linder v. United States</i> , 268 U.S. 5 (1925).....	3

<i>Medtronic, Inc. v. Lohr</i> , 518 U.S. 470 (1996)	6
<i>Metro. Life Ins. Co. v. Massachusetts</i> , 471 U.S. 724 (1985)	3
<i>Pa. State Educ. Ass’n v. Commonwealth Dep’t of Cmty. & Econ. Dev.</i> , 148 A.3d 142 (Pa. 2016)	4
<i>Slaughterhouse Cases</i> , 83 U.S. 36 (1873)	6
<i>Stenger v. Lehigh Valley Hosp. Ctr.</i> , 609 A.2d 796 (Pa. 1992)	5
<i>U.S. v. Park</i> , 421 U.S. 658 (1975)	19
<i>United States v. Facticeau</i> , 89 F.4th 1 (1st Cir. 2023)	14
<i>United States v. Westinghouse Elec. Corp.</i> , 638 F.2d 570 (3d Cir. 1980)	3, 4, 5, 6
<i>Wash. Legal Found. v. Henney</i> , 202 F.3d 331 (D.C. Cir. 2000)	12, 18
<i>Watson v. Maryland</i> , 218 U.S. 173 (1910)	7
<i>Weaver v. Reagen</i> , 886 F.3d 194 (8th Cir. 1989)	11
<i>Whalen v. Roe</i> , 429 U.S. 589 (1977)	4
Constitutional Provisions	
U.S. Const. amend. X	6
Statutes	
21 U.S.C. § 321	14
21 U.S.C. § 331	10, 15, 19
21 U.S.C. § 352	15
21 U.S.C. § 396	14
63 P.S. § 271.15	8
63 P.S. § 271.3	8
63 P.S. § 271.6	8
63 P.S. § 422.22	8
63 P.S. § 422.28	8
63 P.S. § 422.41	8
63 P.S. § 442.10	8

63 P.S. §§ 271.1-271.19.....	8
63 P.S. §§ 422.1-422.51a.....	8
735 Ill. Comp. Stat. 40/28-5, <i>et seq.</i>	9
Cal. Civ. Code §56.109.....	9
Colo. Rev. Stat. §§10-16-121(1)(f), 12-30-121, 13-21-133, 16-3-102, 16-3-301	9
Conn. Gen. Stat. §§19a-17e, 52-146w, 52-146x, 52-571m, 52-571n, 54-155b	9
Mass Gen. Laws ch. 12, §11I½(b)-(d).....	9
Mass. Gen. Laws ch. 147, §63	9
Mass. Gen. Laws ch. 276, §13	9
Md. Code Ann., State Pers. & Pens. §2-312; 2023.....	9
Minn. Laws, ch. 29	9
N.Y. Comp. Codes R. & Regs. tit. 10, §405.7(c)(2).....	9
N.Y. Exec. Law §837-x	9
Or. Rev. Stat. §§15.430, 24.500, 414.769, 435.210, 435.240.....	9
Vt. Stat. Ann. tit. 12, §7301 <i>et seq.</i>	9
Wash. Rev. Code §7.115 <i>et seq.</i>	9
Regulations	
244 Code Mass. Regs. §9.03(13).....	10
28 Pa. Code § 115.27	3
49 Pa. Code § 16.61	8
Other Authorities	
CMS, <i>Article: Off-Label Use of Drugs and Biologicals for Anti-Cancer Chemotherapeutic Regimen</i> (rev'd Nov. 16, 2023).....	15
Coleen Klasmeier, <i>FDA, Medical Communications, and Intended Use-A New Challenge to First and Fifth Amendment Constraints on Government Power</i> , 78 Food & Drug L.J. 263 (2023)	15
FDA, <i>Addendum to Jan 2017 FDA Memo—Additional and Updated Considerations Related to Manufacturer Communications Re Unapproved</i>	

<i>Uses of Approved or Cleared Medical Products</i> (Jan. 2025)	16
FDA, <i>Additional Protections for Children</i> (rev'd Sept. 21, 2015)	18
FDA, <i>Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products; Questions and Answers; Guidance for Industry</i> (Jan. 2025)	12, 16
FDA, <i>Pediatric Ethics</i> (rev'd Jan. 16, 2024)	18
FDA, <i>Understanding Unapproved Use of Approved Drugs "Off Label"</i> (Feb. 5, 2018)	12
Federation of State Medical Boards, <i>Contact a State Medical Board</i> (n.d.)	7
H. Christine Allen et al., <i>Off-Label Medication Use in Children, More Common than We Think: A Systematic Review of the Literature</i> , 111 J. Okla. St. Med. Ass'n 776 (2018)	18
James M. Beck & Elizabeth D. Azari, <i>FDA, Off-Label Use, and Informed Consent: Debunking Myths and Misconceptions</i> , 53 Food & Drug L. J. 71 (1998)	18, 19
James M. Beck, <i>Off-Label Use in the Twenty-First Century: Most Myths and Misconceptions Mitigated</i> , 54 UIC J. Marshall L. Rev. 1 (2021)	17, 18, 19
James T. O'Reilly & Katherine A. Van Tassel, eds., 1 <i>Food and Drug Admin.</i> § 8 (4th ed.)	20
Lewis A. Grossman, <i>Criminalizing Transgender Care</i> , 110 Iowa L. Rev. 281 (2024)	19
Mass. Bd. of Reg. in Medicine Policy 16-01: Policy on Gender Identity and the Physician Profile Program	10
N.J.A.C. Executive Order No. 326 (2023)	9
Nadia N. Sawicki, <i>Character, Competence and the Principles of Medical Discipline</i> , 13 HEALTH CARE L. & POL'Y 285 (2010)	8
Nat'l Cancer Inst., <i>Off-Label Drug Use in Cancer Treatment</i> (rev'd Jan. 13, 2022)	18
Notice of Proposed Rulemaking, <i>Legal Status of Approved Labeling for Prescription Drugs; Prescribing for Uses Unapproved by the Food and Drug Administration</i> , 37 Fed. Reg. 16503 (Aug. 15, 1972)	7
Patricia J. Zettler, <i>Toward Coherent Federal Oversight of Medicine</i> , 52 SAN DIEGO L. REV. 427 (2015)	7, 8

<i>Promotion of Unapproved Drugs and Medical Devices, Testimony Before the S. Comm. on Labor and Human Res.</i> , 104th Cong. (1996)	11
ROBERT C. DERBYSHIRE, <i>MEDICAL LICENSING AND DISCIPLINE IN THE UNITED STATES</i> (1969).....	7
ROBERT I. FIELD, <i>HEALTH CARE REGULATION IN AMERICA: COMPLEXITY, CONFRONTATION, AND COMPROMISE</i> (2007)	7
Ryan Abbott & Ian Ayres, <i>Evidence and Extrapolation: Mechanisms for Regulating Off-Label Uses of Drugs and Devices</i> , 64 Duke L.J. 377 (2014)	11
Steven A. Engel, <i>Whether the Food & Drug Administration Has Jurisdiction Over Articles Intended for Use in Lawful Executions</i> , 43 Op. O.L.C. 81 (2019).....	12, 15
UCLA Sch. of Law Williams Inst., <i>Shield Laws for Reproductive and Gender-Affirming Health Care: A State Law Guide</i>	9

INTRODUCTION AND STATEMENT OF INTERESTS

Pennsylvania Governor Josh Shapiro, Massachusetts, California, Colorado, Connecticut, Delaware, the District of Columbia, Illinois, Maryland, Minnesota, Nevada, New Jersey, New York, Oregon, Vermont, and Washington (Amici) submit this brief in support of the Motion to Limit the *Subpoena Duces Tecum* Issued on June 12, 2025, filed by the Children’s Hospital of Philadelphia (CHOP). Amici are home to hospitals, such as CHOP, that provide essential and life-saving care to thousands of people every year, including gender-affirming care to individuals under the age of 19. These hospitals are at the forefront of biomedical and technological research, and they fuel the economies of Amici, including by creating jobs, spurring innovation, improving residents’ health, and training the future workforce.

The subpoena demands highly confidential patient information without justification. It would allow the government to interfere with the doctor-patient relationship and erode the confidence patients have that their medical records will be kept private. In addition, it seeks to intimidate medical providers from offering critical, medically necessary health care. And it rests on a flawed legal justification that would intrude on the States’ authority to regulate the practice of medicine within their borders. If enforced, the subpoena would place medical providers and hospital administrators in the crosshairs of civil and criminal enforcement mechanisms, including prosecutions, merely for providing essential health care. DOJ’s baseless attempt to sweep the routine prescription and administration of medications for off-label use into federal criminal prohibitions, all in pursuit of its stated goal of ending gender-affirming care, will cause profound disruptions across the entire medical field.

Amici have strong interests in regulating the practice of medicine in their jurisdictions, including by licensing doctors and other medical professionals; implementing standards of care for a wide variety of medical procedures and treatments; and enforcing those standards and other

related regulations. But for these efforts to succeed, patients must have confidence that their private medical records will be kept confidential. Such confidence is essential to protecting the doctor-patient relationship. Permitting DOJ to demand the confidential health information of hundreds of patients based on manufactured justifications would erode the trust between doctors and patients and undermine state efforts to use their regulatory authority to protect that trust.

In briefing in the related matter brought by CHOP patients and families,¹ DOJ attempts to justify its invasion of this traditional sphere of state regulation by citing the federal Food, Drug, and Cosmetic Act (FDCA)—but its interpretation of that statute is exceedingly broad, disruptive, and untethered to precedent and practice. Indeed, DOJ’s interpretation appears to conflict with decades of settled caselaw concerning medical providers’ *use* of approved medications for off-label purposes—something that the statute has never been understood to reach. Moreover, DOJ’s suggestion—that the FDCA’s prohibitions concerning the distribution and labeling of off-label drugs should be applied to the provision of routine medical care and to standard communications between doctors and patients—would impose potential criminal liability to those who administer a sweeping array of health care. DOJ offers no limiting principle: if its interpretation of the FDCA were accepted, entire fields of medicine could see their practitioners at risk of criminal conviction merely for offering evidence-based treatments in accordance with the prevailing standards of care. If CHOP were forced to comply with this subpoena and DOJ were to prevail in its interpretation of the FDCA, it would threaten the health and welfare of the people of Pennsylvania and other Amici, impede core economic activities of Amici, and encroach on the States’ traditional role as the regulators of medicine.

For the reasons advanced below and by CHOP, the Court should grant CHOP’s motion.

¹ DOJ Mem., *In Re: Administrative Subpoena No. 25-1431-014*, No. 25-54, ECF No. 16 (E.D.Pa.).

ARGUMENT

I. If enforced, the subpoena would harm the inherent privacy rights of Amici’s residents.

As sovereigns of their respective territories, States reserve the power to provide for the health, welfare, safety, and security of the people. *See Metro. Life Ins. Co. v. Massachusetts*, 471 U.S. 724, 756 (1985); *see also Linder v. United States*, 268 U.S. 5, 18 (1925); *Bergman v. Parker*, 348 U.S. 26, 32 (1954); *Hillsborough Cnty., Fla. v. Automated Med. Lab’ys, Inc.*, 471 U.S. 707, 719 (1985). Underpinning the common welfare is the right to privacy. As Pennsylvania Supreme Court Justice Musmanno said, of “all the precious privileges and prerogatives in the crown of happiness which every American citizen has the right to wear, none shines with greater luster and imparts more innate satisfaction and soulful contentment to the wearer than the golden, diamond-studded right to be let alone.” *Commonwealth v. Murray*, 223 A.2d 102, 109 (Pa. 1966) (plurality).

DOJ’s subpoena, if enforced, would trample on this right. It demands that CHOP disclose five years of highly sensitive medical records and personally identifying information about adolescent patients and their families. It cannot seriously be disputed that the requested records “contain intimate facts of a personal nature.” *See United States v. Westinghouse Elec. Corp.*, 638 F.2d 570, 577 (3d Cir. 1980). Nor can DOJ dispute that the requested records are the product of the relationship between patient and physician, provided under expectation of confidentiality and in furtherance of personalized medical care. *E.g., Haddad v. Gopal*, 787 A.2d 975, 981 (Pa. Super. 2001) (“Doctors have an obligation to their patients to keep communications, diagnosis, and treatment completely confidential.”); 28 Pa. Code § 115.27.

Under this Circuit’s precedents, this Court must “weigh[] competing interests” to determine whether such an extraordinary intrusion into individual privacy and the doctor-patient

relationship is “justified.” *Westinghouse*, 638 F.2d at 578. Pennsylvania’s constitutional privacy protections, found in Article I of its Constitution, reflect a centuries-old common understanding that privacy rights are inherent and underscore why the balance tips sharply in favor of limiting the subpoena here.

The right to privacy is the “most prominent” right secured by Article I of the Pennsylvania Constitution. *Allegheny Reprod. Health Ctr. v. Pa. Dep’t of Hum. Servs.*, 309 A.3d 808, 899 (Pa. 2024) (plurality). Pennsylvania courts readily agree that the rights protected by Article I of the Pennsylvania Constitution are “inherent to mankind”—that is, “secured rather than bestowed by the Constitution.” *Driscoll v. Corbett*, 69 A.3d 197, 208-09 (Pa. 2013) (discussing how the Pennsylvania Constitution of 1776 was drafted by adherents of natural law philosophers). These inherent rights are “an enumeration of the fundamental human rights possessed by the people of this Commonwealth that are specifically exempted from the powers of Commonwealth government to diminish.” *Allegheny Reprod.*, 309 A.3d at 898 (quoting *League of Women Voters v. Commonwealth*, 178 A.3d 737, 803 (Pa. 2018)).

There are at least three components of the right to privacy. *See generally Allegheny Reprod.*, 309 A.3d at 900-05 (summarizing development of privacy jurisprudence). *First* is “the interest in avoiding disclosure of personal matters,” also known as the right to informational privacy, which protects (among other things) “names, addresses, social security numbers, and telephone numbers.” *Id.* at 902-03; *see, e.g., Pa. State Educ. Ass’n v. Commonwealth Dep’t of Cmty. & Econ. Dev.*, 148 A.3d 142, 158 (Pa. 2016); *Denoncourt v. State Ethics Commission*, 470 A.2d 945, 947-48 (Pa. 1983) (plurality). *Second* is the “interest in having independence to make certain kinds of important decisions.” *Allegheny Reprod.*, 309 A.3d at 900; *see, e.g., Whalen v. Roe*, 429 U.S. 589, 599-600 & n.26 (1977); *Coleman v. W.C.A.B.*, 842 A.2d 349, 354 (Pa. 2004)

(linking the common law “right to be free of bodily invasion and to refuse medical treatment” with the “privacy interest in preserving [] bodily integrity”); *Stenger v. Lehigh Valley Hosp. Ctr.*, 609 A.2d 796, 800 (Pa. 1992) (citing *Whalen*); *Denoncourt*, 470 A.2d at 947-48 (same). And *third* is the “freedom from government intrusion into an individual’s bodily integrity.” *Allegheny Reprod.*, 309 A.3d at 904-05; *see, e.g., John M. v. Paula T.*, 571 A.2d 1380, 1386 (Pa. 1990).

Information revealed through the doctor-patient relationship implicates all three components: it concerns deeply personal and sensitive topics; it is provided by patients for the purpose of receiving medical advice and making informed decisions about physical and behavioral health needs; and it is derived directly from the patient’s physical body.

As a result, courts have long recognized that the right to privacy covers medical records and health information. *See, e.g., Westinghouse*, 638 F.2d at 577 (acknowledging widespread “recognition that information concerning one’s body has a special character” that is “well within the ambit of materials entitled to privacy protection”); *Allegheny Reprod.*, 309 A.3d at 906 (“The right to make healthcare decisions related to reproduction is a core important right encompassed by the enmeshed privacy interest protected by our Charter.”); *Commonwealth v. Shaw*, 770 A.2d 295, 299 (Pa. 2001) (“The right to privacy extends to medical records of patients.”); *Stenger*, 609 A.2d at 800 (in matter involving discovery and records related to blood donation, recognizing that the “well-settled” right of privacy requires the Court “to avoid unjustified intrusions into the private zone of our citizens’ lives”); *In re June 1979 Allegheny Cnty. Investigating Grand Jury*, 415 A.2d 73, 77-78 (Pa. 1980) (“Disclosure of confidences made by a patient to a physician, or even of medical data concerning the individual patient could, under certain circumstances, pose such a serious threat to a patient’s right not to have personal matters revealed that it would be impermissible under either the United States Constitution or the Pennsylvania Constitution.”); *In*

re “B,” 394 A.2d 419, 425 (Pa. 1978) (plurality) (“in Pennsylvania ... [a] patient’s right to prevent disclosure” of sensitive medical information “is constitutionally based”).

DOJ’s subpoena, if enforced, would harm the innate privacy rights CHOP patients and their families have in their medical records and personal health information—and ultimately, the privacy rights of all residents in Amici states. DOJ asks this Court to allow an extraordinary intrusion into core health information: patient names, dates of birth, social security numbers, addresses, parent/guardian information, documents related to patient intake, and “documents relating to the clinical indications, diagnoses, or assessments,” among other items. But DOJ has offered no credible “need for access” to this deeply personal and sensitive information. *Westinghouse*, 638 F.2d at 578. Instead, as explained below and by CHOP, the subpoena is properly seen as a fishing expedition to substantiate a specious legal theory that would both intrude on rights reserved to the States under the Tenth Amendment and jeopardize the entire practice of medicine.

II. If enforced, the subpoena would interfere with Amici’s authority to regulate the practice of medicine.

The Tenth Amendment reserves for the States all rights and powers “not delegated to the United States” federal government. U.S. Const. amend. X. Commonly referred to as “traditional state police powers,” the rights and powers of the States include the “power to protect the health and safety of their citizens.” *Medtronic, Inc. v. Lohr*, 518 U.S. 470, 475 (1996); *see also Slaughterhouse Cases*, 83 U.S. 36, 62 (1873) (describing the police power as extending “to the protection of the lives, limbs, health, comfort, and quiet of all persons ... within the State”). Since at least 1889, the authority to regulate the practice of medicine has been among these powers. *Dent v. West Virginia*, 129 U.S. 114, 122 (1889). Though Congress may regulate interstate commerce, the Executive may not distort the meaning of federal statutes in order to

disrupt a State’s medical regulatory framework by inventing novel forms of criminal activity. *See Gonzales v. Oregon*, 546 U.S. 243, 269-70 (2006) (holding that Controlled Substances Act did not prohibit Oregon doctors from prescribing medication for the purpose of medical aid in dying, where such care had been enacted through ballot measure). Courts have upheld a broad set of “state medical practice laws against constitutional challenges, making clear that states are generally authorized to legislate in the medical practice area.”²

To avoid encroaching on the practice of medicine, federal agencies, including the Food and Drug Administration, have historically recognized that the FDCA does not regulate the off-label *use* of medications. *Buckman Co. v. Plaintiffs’ Legal Comm.*, 531 U.S. 341, 350 (2001); *see also, e.g.*, Notice of Proposed Rulemaking, *Legal Status of Approved Labeling for Prescription Drugs; Prescribing for Uses Unapproved by the Food and Drug Administration*, 37 Fed. Reg. 16503, 16503 (Aug. 15, 1972).

1. States have exercised their power to regulate medicine in various ways. Perhaps most significantly, states regulate the practice of medicine by defining the scope of medical practice and requiring medical licenses for practitioners.³ Since 1895, all states have boards that oversee the licensing of medical professionals.⁴ Fundamental and consistent requirements for

² Patricia J. Zettler, *Toward Coherent Federal Oversight of Medicine*, 52 SAN DIEGO L. REV. 427, 448 (2015); *see also Hillsborough Cnty.*, 471 U.S. at 719 (stating “the regulation of health and safety matters is primarily, and historically, a matter of local concern”); *Watson v. Maryland*, 218 U.S. 173, 176 (1910) (the police power of the states extends to the regulation of certain trades and callings, particularly those which closely concern the public health” and discussing licensing of medical practitioners); *Gonzales v. Carhart*, 550 U.S. 124, 157 (2007) (“Under our precedents it is clear the State has a significant role to play in regulating the medical profession.”); *Barsky v. Bd. of Regents*, 347 U.S. 442, 451 (1954) (indicating that the state has “legitimate concern for maintaining high standards of professional conduct” in the practice of medicine); *Buckman*, 531 U.S. at 348 (identifying “historic primacy of state regulation of matters of health and safety”).

³ Zettler, *supra* note 2, at 449-50 (citing ROBERT I. FIELD, *HEALTH CARE REGULATION IN AMERICA: COMPLEXITY, CONFRONTATION, AND COMPROMISE* 19 (2007) (stating that the “cornerstone” of medical practice regulation is states’ licensing schemes)).

⁴ ROBERT C. DERBYSHIRE, *MEDICAL LICENSING AND DISCIPLINE IN THE UNITED STATES* 8 (1969); Zettler, *supra* note 2, at 450; *see also* Federation of State Medical Boards, *Contact a State Medical Board* (*n.d.*), <https://www.fsmb.org/contact-a-state-medical-board>.

obtaining a medical license across states include graduation from an accredited medical school, completing one or more years of residency or fellowship, and passing a licensing examination.⁵ Additional requirements may include interviews, a documented lack of criminal history, and medical malpractice insurance coverage.⁶

In Pennsylvania, the State Boards of Medicine and Osteopathic Medicine are responsible for the licensure, regulation, and discipline of medical and osteopathic physicians and certain other health professionals in the Commonwealth. *See* 63 P.S. §§ 422.1-422.51a; *id.* §§ 271.1-271.19. Medical and osteopathic physicians must be licensed to engage in the practice of medicine in Pennsylvania. *See id.* §§ 422.28, 442.10; *id.* § 271.3. They must meet minimum qualifications for licensure, including education, training, and examination requirements. *See id.* § 422.22; *id.* § 271.6. The Boards seek to ensure that physicians deliver competent, ethical, and legally compliant care throughout the Commonwealth.

To further these duties, the State Board of Medicine is specifically empowered to adopt regulations that “define the accepted standard of care” for the profession. *Id.* § 422.41(8)(ii). Where the Board has not adopted an applicable regulation, the relevant standard of care is “that which would be normally exercised by the average professional of the same kind in [the] Commonwealth under the circumstances.” *Id.* The Boards are authorized to discipline any licensed doctor who “provides a medical service at a level beneath the accepted standard of care” or engages in “incompetence, gross negligence, or repeated acts of negligence or incompetence in the practice of medicine or surgery.” *Id.* § 422.41; *id.* § 271.15; 49 Pa. Code § 16.61.

Thus, it is the responsibility of these licensing boards—and not the federal government—

⁵ Zettler, *supra* note 2, at 450 (citing Nadia N. Sawicki, *Character, Competence and the Principles of Medical Discipline*, 13 HEALTH CARE L. & POL’Y 285, 290 (2010)).

⁶ Zettler, *supra* note 2, at 450.

to determine whether physicians have engaged in conduct that is inconsistent with the standard of care. And in making this assessment, the boards look to the practice of medicine in the Commonwealth, rather than dictates from Washington, D.C. Yet the subpoena rests on a misguided theory that would allow DOJ to dictate the medical standard of care in every state based on its own tortured reading of the FDCA. *See infra* Part III. Such a theory would have sweeping implications beyond gender-affirming care; among others, it would threaten physicians across the country with criminal prosecution for providing care that is entirely permissible in their home state and, in their clinical judgment, in the best interest of their patients.

2. In Pennsylvania—and in all Amici states—gender-affirming care remains legal and accessible. Pennsylvania’s licensing boards have never determined that gender-affirming care that is consistent with the standard of care in the Commonwealth is inappropriate in any way. Likewise, the off-label prescription of medicine is permissible, so long as it is done consistently with the appropriate standard of care.

Other states have taken more formal steps to safeguard access to gender-affirming care for transgender people, exercising their sovereign judgment that such safeguards promote public health and wellbeing. For instance, Massachusetts and many other Amici expressly recognize a legal right to gender-affirming care and have enacted laws intended to protect people in their States who access, provide, or assist with the provision of that care from civil or criminal penalties by out-of-state jurisdictions that outlaw it.⁷ Some State licensing boards—such as the

⁷ *See, e.g.*, Mass. Gen. Laws ch. 12, § 11I½(b)-(d); Mass. Gen. Laws ch. 147, § 63; Mass. Gen. Laws ch. 276, § 13; Cal. Civ. Code § 56.109; Colo. Rev. Stat. §§ 10-16-121(1)(f), 12-30-121, 13-21-133, 16-3-102, 16-3-301; Conn. Gen. Stat. §§ 19a-17e, 52-146w, 52-146x, 52-571m, 52-571n, 54-155b; 735 Ill. Comp. Stat. 40/28-5, *et seq.*; Md. Code Ann., State Pers. & Pens. § 2-312; 2023 Minn. Laws ch. 29; Minn. Stat. § 260.925; N.Y. Exec. Law § 837-x; N.Y. Comp. Codes R. & Regs. tit. 10, § 405.7(c)(2); Or. Rev. Stat. §§ 15.430, 24.500, 414.769, 435.210, 435.240; Vt. Stat. Ann. tit. 12, § 7301 *et seq.*; Wash. Rev. Code § 7.115 *et seq.*; N.J.A.C. Executive Order No. 326 (2023); *see also* UCLA Sch. of Law Williams Inst., *Shield Laws for Reproductive and Gender-Affirming Health Care: A State Law Guide*, <https://williamsinstitute.law.ucla.edu/publications/shield-laws-fact-sheets>.

Boards of Registration in Medicine and in Nursing in Massachusetts—also instruct licensees that they shall not withhold or deny care based on a patient’s gender identity.⁸

If enforced, DOJ’s subpoena to CHOP would threaten all states’ ability to regulate the practice of medicine. It is part of an effort to end a specific type of care for a particularly vulnerable population, even though there is no federal law prohibiting such care. DOJ’s sweeping requests for sensitive information—including records of all patients who have received gender-affirming care—is an extraordinary attempt to subvert the policy and judgment of the states as the traditional regulators of the practice of medicine. The broadside attack by DOJ undermines the States’ sovereign authority in protecting the health and safety of our residents.

III. DOJ adopts an overly expansive—and unprecedented—interpretation of the FDCA.

In its briefing in the related matter, DOJ justifies its subpoena through a novel and unreasonable interpretation of the FDCA. Contrary to established practice and precedent,⁹ DOJ now interprets the FDCA to regulate the practice of medicine. It does so by reading 21 U.S.C. § 331(a) and (d) to cover both the routine administration of approved drugs for off-label purposes and communications between providers and patients about those drugs—medical practices and elements of the doctor-patient relationship that long-settled law says the Act does not touch. The implications of this reading are enormous: DOJ’s interpretation of the FDCA will have widespread and disastrous implications across the field of medicine (with particularly significant harms in some critical areas of care, such as pediatrics and oncology, where off-label

⁸ See 244 Code Mass. Regs. § 9.03(13); Mass. Bd. of Reg. in Medicine Policy 16-01: Policy on Gender Identity and the Physician Profile Program, *available at* <https://www.mass.gov/lists/physician-regulations-policies-and-guidelines>.

⁹ *E.g., Ass’n of Am. Physicians & Surgeons v. U.S. Food & Drug Admin.*, 13 F.4th 531, 534 (6th Cir. 2021) (citing *Buckman*, 531 U.S. at 350-51) (“Although the Act regulates a manufacturer’s distribution of drugs, it does not go further by regulating a doctor’s practice of medicine.”).

use is especially prevalent) and could actively discourage open communication between health care providers and their patients about the medications they receive.

A. Off-label use of approved drugs where medically appropriate is permissible under the FDCA.

The FDA has regulatory authority to approve prescription drugs to be marketed and labeled for certain uses. Within the FDA, the Center for Drug Evaluation and Research (CDER) evaluates prescription drugs' safety and efficacy through premarket approval.¹⁰ Premarket approval is a multi-step process (involving multiple applications and stepped authorizations) that ultimately results in approval of a drug to be marketed and sold for a particular indication (use) in a specific population.¹¹ The FDA's approval also includes an approved drug label, which is "a summary of the evidence supporting the safe and effective use of the drug."¹²

The process by which the FDA approves drugs for particular indications is "not intended to limit or interfere with the practice of medicine nor to preclude physicians from using their best judgment in the interest of the patient," but instead "is intended to ensure that drugs meet certain statutory standards for safety and effectiveness, manufacturing and controls, and labeling[.]" *Weaver v. Reagen*, 886 F.3d 194, 198 (8th Cir. 1989). Consequently, it is well-settled that "[a]s a general matter, once a drug is approved, physicians may *prescribe* the drug without restriction."¹³ The FDA itself has repeatedly made public statements to this effect,¹⁴ including as

¹⁰ Ryan Abbott & Ian Ayres, *Evidence and Extrapolation: Mechanisms for Regulating Off-Label Uses of Drugs and Devices*, 64 Duke L.J. 377, 383 (2014).

¹¹ Abbott & Ayres, *supra* note 10, at 384.

¹² Abbott & Ayres, *supra* note 10, at 384-85.

¹³ Abbott & Ayres, *supra* note 10, at 387; *see also* *Buckman*, 531 U.S. at 350 (explaining that "off-label" use of medical devices "is an accepted and necessary corollary of the FDA's mission to regulate in this area without directly interfering with the practice of medicine").

¹⁴ *See, e.g.*, Abbott & Ayres, *supra* note 10, at 387 n.32 (quoting *Promotion of Unapproved Drugs and Medical Devices, Testimony Before the S. Comm. on Labor and Human Res.*, 104th Cong. (1996) (statement of William B. Schultz, Deputy Comm'r for Policy, Food & Drug Admin.) ("The legislative history of the Federal Food, Drug, and

recently as this year,¹⁵ and its own website specifically says that once the agency “approves a drug, health care providers generally may prescribe the drug for unapproved use when they judge that it is medically appropriate for their patient.”¹⁶ Courts also routinely recognize that the FDCA permits doctors to prescribe medications off label. *See, e.g., In re Schering Plough Corp. Intron/Temodar Consumer Class Action*, 678 F.3d 235, 240 (3d Cir. 2012) (“Because the FDCA does not regulate the practice of medicine, physicians may lawfully prescribe drugs for off-label uses.”); *In re Zofran (Ondansetron) Prods. Liab. Litig.*, 541 F. Supp. 3d 164, 173 (D. Mass. 2021), *aff’d*, 57 F.4th 327 (1st Cir. 2023) (“It is generally lawful for physicians to prescribe medications for purposes for which they have not been FDA-approved.”); *Wash. Legal Found. v. Henney*, 202 F.3d 331, 333 (D.C. Cir. 2000) (“A physician may prescribe a legal drug to serve any purpose that he or she deems appropriate, regardless of whether the drug has been approved for that use by the FDA.”). And DOJ’s own Office of Legal Counsel (OLC) concurs, writing that “[a]s a general matter, [the] FDA does not regulate the practice of medicine, which includes ‘off-label’ prescribing.”¹⁷ As a result, off-label usage of drugs and devices is an important part of the practice of medicine, particularly in fields such as pediatrics and oncology. *See infra* Part III.C.

Cosmetic Act indicates that Congress did not intend FDA to interfere with the practice of medicine. Thus, once a drug is approved for marketing, FDA does not generally regulate how, and for what uses, physicians prescribe that drug. A physician may prescribe a drug for uses or in treatment regimens or patient populations that are not listed in the FDA-approved labeling.”).

¹⁵ *See* FDA, *Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products; Questions and Answers; Guidance for Industry* 8-9 (Jan. 2025), <https://www.fda.gov/media/184871/download> (acknowledging various circumstances in which health care providers may validly prescribe drugs for off-label use).

¹⁶ FDA, *Understanding Unapproved Use of Approved Drugs “Off Label”* (Feb. 5, 2018), <https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label>.

¹⁷ Steven A. Engel, *Whether the Food & Drug Administration Has Jurisdiction Over Articles Intended for Use in Lawful Executions*, 43 Op. O.L.C. 81, 85 (2019).

B. DOJ wrongly sweeps off-label prescribing and dispensing into the FDCA’s prohibitions concerning distribution and promotion of unapproved drugs.

DOJ admits, as it must, that physicians “are permitted to prescribe an FDA-approved drug for an unapproved use.” Hsiao Decl. ¶ 12, *In Re: Administrative Subpoena No. 25-1431-014*, No. 25-54, ECF No. 16-1 (E.D.Pa. Oct. 6, 2025). Recognizing this limitation, DOJ instead improperly characterizes the lawful practice of a clinician prescribing and communicating about FDA-approved drugs for off-label uses as violations of the FDCA’s prohibitions on the *distribution* and *labeling* of drugs for unapproved uses. DOJ’s reading of the FDCA is wrong, has no basis in law, and, if adopted, will have broad implications for the practice of medicine.

1. Purchasing, storing, and administering approved medications does not give rise to criminal liability under the FDCA.

DOJ wrongly claims, without support, that the FDCA subjects hospital staff and medical providers to criminal liability when they purchase, store, and administer an approved drug for a purpose other than that approved by the FDA. To get to that conclusion, DOJ offers an elaborate, multi-step interpretation of the FDCA, which would (for the first time) make providers criminally liable for purchasing, storing, and administering a drug for an off-label use. It says, *first*, that “introducing a such ‘new drug’ into interstate commerce without an FDA-approved indication is unlawful,” Hsiao Decl. ¶ 22; *second*, drugs that are used to treat conditions for which they have not been specifically approved “constitute[s] unapproved new drugs under federal law,” *id.*; *third*, that “distribution for that unapproved indication violates the FDCA and is a federal crime,” *id.*; and *finally*, that health care providers who “purchase, store, and administer the drug ... [are] in the chain of distribution of that drug,” *id.* ¶ 23. The government’s tortured analysis is at odds with explicit statutory language as well as accepted practice and precedent, and would make hospital pharmacies, hospital departments, and even retail pharmacies liable for routine parts of their practice.

The specific drugs highlighted by DOJ as potentially exposing providers to criminal liability are puberty blockers, which are “typically implants or injectables,” *id.* ¶ 23, that are administered by medical providers at their offices. Implanted puberty blockers are devices under 21 U.S.C. § 321(h)(1), which the FDCA explicitly allows providers to administer to patients for off-label uses. *See* 21 U.S.C. § 396 (“Nothing in this chapter shall be construed to limit or interfere with the authority of a health care practitioner to prescribe or administer any legally marketed device to a patient for any condition or disease within a legitimate health care practitioner-patient relationship.”). Contrary to DOJ’s interpretation, providers who are purchasing, storing, and administering such implants or injectables for an off-label use in their places of practice are thus not unlawfully “distributing” the drug or device within the meaning of the FDCA. *Contra* Hsiao Decl. ¶ 23. The suggestion that FDCA liability attaches to anyone who administers an approved device for an unapproved but medically indicated purpose is thus belied by the statutory framework. *See* 21 U.S.C. § 396.

Moreover, the prescription or administration of an approved medication or device off label by a medical provider does not render it a “new drug” for purposes of the FDCA, nor render it “unapproved.” Rather, it is well established that “medical professionals may lawfully prescribe and administer a device for an off-label use as long as that device has received [FDA] clearance for any intended use.” *United States v. Facticeau*, 89 F.4th 1, 15 (1st Cir. 2023), *cert. denied*, 145 S. Ct. 137 (2024). If this were not so, virtually all drugs in common use across the United States would be deemed in violation of the statute if prescribed for any purpose other than what is specified on the label.

Finally, the idea that a provider becomes an unlawful “distributor” if the provider purchases, stores, and administers a drug to a patient is in tension with the widely accepted and

permissible off-label dispensing of drugs. Providers regularly purchase, store, and administer drugs for off-label uses in hospital settings, residential facilities like nursing homes or rehabilitation centers, and certain outpatient treatment centers because such treatment is medically appropriate. Indeed, DOJ's interpretation would virtually upend oncology practices, where the purchase, storage, and on-site administration of chemotherapeutic drugs for off-label uses is not only extremely common but also recognized as vital by CMS.¹⁸ DOJ's misplaced theory of provider liability would endanger these routine and widespread methods of care and would effectively nullify the longstanding recognition of the propriety and legality of off-label prescribing by duly licensed medical professionals. *See, e.g., In re Schering*, 678 F.3d at 240 (“[P]hysicians may lawfully prescribe drugs for off-label uses.”). Indeed, DOJ OLC has noted that the FDCA's prohibitions on distribution generally are not applicable to providers, observing that “[w]hile the FDCA bars a manufacturer or distributor from selling any drug or device for an unapproved use, physicians may, with limited exceptions, prescribe and administer FDA-approved drugs and devices for unapproved uses.”¹⁹

2. Practitioners' provision of information about off-label uses does not subject medical providers to liability for misbranding.

Under the FDCA, a drug or device is deemed “misbranded” if “its labeling is false or misleading in any particular.” 21 U.S.C. § 352(a)(1). The FDCA statutory framework bars the introduction or delivery for introduction into interstate commerce of any food, drug, device ... that is adulterated or misbranded.” 21 U.S.C. § 331(a). Until this matter, the FDA had construed § 331(a) in the context of misbranding or mislabeling as applying only to “firms,” *i.e.*,

¹⁸ Coleen Klasmeier, *FDA, Medical Communications, and Intended Use-A New Challenge to First and Fifth Amendment Constraints on Government Power*, 78 Food & Drug L.J. 263, 271 (2023); *see CMS, Article: Off-Label Use of Drugs and Biologicals for Anti-Cancer Chemotherapeutic Regimen* (rev'd Nov. 16, 2023), <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=58113>.

¹⁹ Engel, *supra* note 17, at 85.

pharmaceutical companies, or their paid consultants—not to unaffiliated health care providers.²⁰

Yet the DOJ now suggests that medical providers could be liable under the FDCA’s prohibition on distributing “misbranded” medications merely for explaining an off-label use of an already-approved drug or device to patients. *See* Hsiao Decl. ¶¶ 13-16. DOJ observes that the FDCA defines labeling broadly to include material that “supplements, explains, or is designed for use with the drug,” including things like flyers or instruction sheets. *Id.* ¶ 15. It then extrapolates that if a person “distributes (or causes the distribution of) an approved drug with false or misleading labeling for an unapproved use, [they] could possibly be charged with misbranding the drug or distributing a misbranded drug.” *Id.* ¶ 16. Together with its assertion that a medical provider who stores or administers such a drug is in the chain of distribution, DOJ’s claim here thus implies that a doctor who provides her patient with an instruction sheet explaining the off-label drug she is administering could be subject to criminal liability for misbranding under the FDCA.

The construction adopted by DOJ in the related matter thus departs both from the typical conduct and typical actors usually considered to be within the scope of § 331(a). Such a construction appears to be a sharp departure from the federal government’s own past practice. Amici are unaware of any instance when DOJ or FDA has extended liability to a practitioner in the circumstances here—that is, when, with no connection to any firm-supported promotional

²⁰ *See, e.g.,* FDA, *Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products; Questions and Answers; Guidance for Industry* 8-9 (Jan. 2025), <https://www.fda.gov/media/184871/download> (acknowledging various circumstances in which health care providers may validly prescribe drugs for off-label use). (Note that although this guidance is final, it is “not for current implementation,” as it is currently before the Office of Management and Budget for approval of information collection provisions. *See id.* at 29.) Moreover, even in circumstances involving paid promotional activity (which is, again, not at issue here), where the “communications” between the pharmaceutical company and provider are truthful, the FDA has recognized that there are First Amendment constraints on their ability to charge such communications as “misbranding.” *See, e.g.,* FDA, *Addendum to Jan 2017 FDA Memo—Additional and Updated Considerations Related to Manufacturer Communications Re Unapproved Uses of Approved or Cleared Medical Products* (Jan. 2025), <https://www.regulations.gov/document/FDA-2016-N-1149-0107>.

activity (such as paid peer-to-peer presentations), the practitioner merely prescribes and provides information about an off-label drug to a patient.

The implications of DOJ’s adopted construction are considerable. Under this interpretation, if a provider consults with a patient, suggests off-label use of a medication, and provides the patient with materials explaining the off-label use of that medication, that provider could potentially have “distributed” a “misbranded” drug. Such a broadening of the scope of the FDCA inserts the government into the exam room to regulate conversations between providers and their patients about possible treatment options. Not only does this have implications for the efficacy of care a medical professional can provide, it also inhibits a patient’s ability to fully understand and give informed consent to certain procedures and medications prescribed off label.

C. DOJ’s expansive interpretation of the FDCA jeopardizes entire fields of medicine.

DOJ’s baseless interpretation of the FDCA—that off-label administration of a drug can constitute unlawful distribution, and providing instructions for an off-label drug can constitute unlawful branding—would have devastating and far-reaching effects that go far beyond the narrow field of gender-affirming care. Recent estimates suggest that between 20 and 50 percent of all prescriptions are for off-label indications.²¹ Further, providers in all medical fields regularly purchase and administer drugs at their place of practice: in hospitals, where providers dispense medication in emergency departments, inpatient units, and oncology units; in residential facilities like nursing homes or rehabilitation centers for eating disorders; or in certain outpatient treatment centers. And as discussed above, medical devices that must be implanted or inserted by medical professionals, such as chemotherapy ports, knee replacements, or indeed any surgical

²¹ James M. Beck, *Off-Label Use in the Twenty-First Century: Most Myths and Misconceptions Mitigated*, 54 UIC J. Marshall L. Rev. 1, 25 & n.112 (2021).

device, are necessarily purchased and stored on-site. DOJ's interpretation of the FDCA would lead to sweeping criminalization of providers in all these settings who purchase, store, prescribe, dispense, and explain medication to patients for routine off-label use.

Furthermore, "the prescription of drugs for unapproved uses ... is *ubiquitous* in certain specialties." *Wash. Legal Found.*, 202 F.3d at 333 (emphasis added). To give one example, providers in oncology units very commonly administer a variety of cancer treatments off label, as several cancer-treating medications are effective for more than one type of cancer, and providers often employ combination chemotherapy.²² As a result, some scholars estimate that 50 to 75 percent of drug use in oncology settings occurs off label.²³ Over time, other fields where off-label use of drugs and medical devices has been particularly prominent have included heart and circulatory disease, AIDS, kidney disease requiring dialysis, osteoporosis, spinal fusion surgery, rare diseases, and psychiatry.²⁴

Salient to the dispute now before this Court, one area where off-label prescribing is especially widespread is pediatrics. Data on the effects of drugs on children is less available than that for adults for a variety of reasons, "including unfamiliarity with age-related developmental pharmacology in pediatric patients, ethical considerations with conducting pediatric research, and a lack of financial incentive for the pharmaceutical industry."²⁵ This lack of data in turn

²² See Nat'l Cancer Inst., *Off-Label Drug Use in Cancer Treatment* (rev'd Jan. 13, 2022), <https://www.cancer.gov/about-cancer/treatment/drugs/off-label>.

²³ Beck, *supra* note 21, at 25-26 & n.113.

²⁴ James M. Beck & Elizabeth D. Azari, *FDA, Off-Label Use, and Informed Consent: Debunking Myths and Misconceptions*, 53 Food & Drug L. J. 71, 80 (1998).

²⁵ H. Christine Allen et al., *Off-Label Medication Use in Children, More Common than We Think: A Systematic Review of the Literature*, 111 J. Okla. St. Med. Ass'n 776, 777 (2018); see also FDA, *Pediatric Ethics* (rev'd Jan. 16, 2024), <https://www.fda.gov/science-research/pediatrics/pediatric-ethics>; FDA, *Additional Protections for Children* (rev'd Sept. 21, 2015), <https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/additional-protections-children>.

drives a relative paucity of FDA approvals of drugs for pediatric indications²⁶—indeed, many drugs carry a so-called “orphaning clause” disclaimer as to pediatric use in light of the absence of sufficient studies.²⁷ Consequently, some studies estimate that as much as 80 percent of drugs prescribed for children are prescribed for off-label uses.²⁸

DOJ’s groundless attempt to shoehorn routine parts of the off-label prescription and administration of medications into the FDCA’s criminal prohibitions in pursuit of its stated goal of “ending” gender-affirming care, DOJ Mem. at 18, *In Re: Administrative Subpoena No. 25-1431-014*, No. 25-54, ECF No. 16 (E.D.Pa. Oct. 6, 2025), threatens an enormous range of medical care in a wide variety of fields. While this subpoena is concerned with gender-affirming care for adolescents, nothing about DOJ’s interpretation of the FDCA offers any kind of limiting principle that would cabin its criminalizing effect. Rather, DOJ’s efforts to apply the FDCA’s criminal provisions concerning distribution and branding to routine off-label prescribing jeopardizes the availability of medical care for many who need it the most.

The implications and consequences of adopting DOJ’s interpretation of the FDCA are even more dire considering DOJ’s allusions to strict criminal liability. As DOJ notes, the violation of 21 U.S.C. § 331—the criminal provision of the FDCA that, among other things, addresses the distribution and labeling of drugs and medical devices—“is punished as a strict liability misdemeanor without any proof of criminal intent.” Hsiao Decl. ¶ 19 (citing *U.S. v. Park*, 421 U.S. 658, 672-73 (1975)). Under what is referred to as the *Park* doctrine, this liability is extended to corporate officers. *Park*, 421 U.S. at 672-73. In addressing the particulars of its subpoena to CHOP, DOJ in turn references those same strict liability provisions as justifying its

²⁶ Lewis A. Grossman, *Criminalizing Transgender Care*, 110 Iowa L. Rev. 281, 310 (2024).

²⁷ Beck & Azari, *supra* note 24, at 80 n.81.

²⁸ Beck, *supra* note 21, at 25-26 & n.114.

request for information on the personnel at CHOP responsible for the direction of prescribing and marketing practices. Hsiao Decl. ¶ 38. The implication is clear: under DOJ’s read of the FDCA and the *Park* doctrine, it intends to hold hospital administrators, doctors, and other providers strictly liable for perceived criminal violations of the statute.²⁹

Read together with its expansive view of the distribution and labeling provisions of the FDCA, DOJ’s invocation of the *Park* doctrine reflects a shocking threat: the federal government aims to prosecute medical providers and hospital administrators for federal crimes based on their routine prescription and administration of medication and communication with patients about the treatments they are receiving. Even the threat of such prosecution flatly contradicts the well-settled notion that the FDCA does not exist to regulate doctors’ practice of medicine, *see, e.g., Ass’n of Am. Physicians & Surgeons*, 13 F.4th at 534, and promises to have profound effects on the provision of health care across the country. The effects would be devastating, particularly in states like Pennsylvania that see significant economic activity from the health care, biotech, and life sciences industries. This Court should reject DOJ’s efforts to use the cudgel of criminal liability to intimidate the doctors and administrators who care for our communities.

CONCLUSION

For the foregoing reasons, Amici respectfully encourage the Court to grant CHOP’s motion to limit the subpoena.

²⁹ Indeed, some critics of the *Park* doctrine “have suggested that the concept of liability for chief executives may become merely a ‘hostage’ rule under which criminal sanctions against individual executives are used as leverage to exact strict compliance with FDA requirements with a minimal expenditure of government resources.” James T. O’Reilly & Katherine A. Van Tassel, eds., 1 *Food and Drug Admin.* § 8:4 (4th ed.) (Westlaw Nov. 2023 update); *see also id.* at § 8:5 (discussing doctrine’s “potential for abuse, using criminal threats as leverage to demand extrastatutory remedies”).

DATE: October 27, 2025

ANDREA JOY CAMPBELL
Attorney General of Massachusetts
ALLYSON SLATER
Director, Reproductive Justice Unit
ADAM M. CAMBIER
MORGAN CARMEN
JAK KUNDL
Assistant Attorneys General
One Ashburton Place
Boston, MA 02108
Tel.: (617) 727-2200
adam.cambier@mass.gov

*Attorneys for the Commonwealth of
Massachusetts*

Respectfully submitted,

JENNIFER SELBER
General Counsel
MICHAEL J. FISCHER
Executive Deputy General Counsel

/s/ Aimee D. Thomson

AIMEE D. THOMSON
Deputy General Counsel
Governor's Office of General Counsel
30 N. 3rd St., Suite 200
Harrisburg, PA 17101
Tel.: (223) 234-4986
aimeethomson@pa.gov

Attorneys for Governor Josh Shapiro

ROB BONTA
Attorney General of California
1300 I St.
Sacramento, CA 95814

PHILIP J. WEISER
Attorney General of Colorado
1300 Broadway, 10th Floor
Denver, CO 80203

WILLIAM TONG
Attorney General of Connecticut
165 Capitol Ave.
Hartford, CT 06106

KATHLEEN JENNINGS
Attorney General of Delaware
820 N. French St.
Wilmington, DE 19801

BRIAN L. SCHWALB
Attorney General of the District of Columbia
400 6th St. NW
Washington, DC 20001

KWAME RAOUL
Attorney General of Illinois
115 South LaSalle St.
Chicago, IL 60603

ANTHONY G. BROWN
Attorney General of Maryland
200 St. Paul Place, 20th Floor
Baltimore, MD 21202

KEITH ELLISON
Attorney General of Minnesota
102 State Capitol
75 Rev. Dr. Martin Luther King Jr. Blvd.
St. Paul, MN 55155

AARON D. FORD
Attorney General of Nevada
100 N. Carson St.
Carson City, NV 89701

MATTHEW J. PLATKIN
Attorney General of New Jersey
Richard J. Hughes Justice Complex
25 Market St.
Trenton, NJ 08625

LETITIA JAMES
Attorney General of New York
28 Liberty St.
New York, NY 10005

DAN RAYFIELD
Attorney General of Oregon
1162 Court St. NE
Salem, OR 97301

CHARITY R. CLARK
Attorney General of Vermont
109 State St.
Montpelier, VT 05609

NICHOLAS W. BROWN
Attorney General of Washington
P.O. Box 40100
Olympia, WA 98504

CERTIFICATE OF SERVICE

I, Aimee D. Thomson, hereby certify that I have this day, October 27, 2025, served the foregoing document upon all parties of record by electronically filing to all ECF-registered parties.

/s/ Aimee D. Thomson
Aimee D. Thomson